Cargando…

Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020

BACKGROUND: Malignant tumors of reproductive system seriously threaten women’s life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiting, Wang, Zhihong, Huang, Dongmei, Deng, Kehong, Wang, Qian, Li, Cancan, Zhu, Jicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730658/
https://www.ncbi.nlm.nih.gov/pubmed/36476597
http://dx.doi.org/10.1186/s12905-022-02104-2
_version_ 1784845726603280384
author Han, Xiting
Wang, Zhihong
Huang, Dongmei
Deng, Kehong
Wang, Qian
Li, Cancan
Zhu, Jicun
author_facet Han, Xiting
Wang, Zhihong
Huang, Dongmei
Deng, Kehong
Wang, Qian
Li, Cancan
Zhu, Jicun
author_sort Han, Xiting
collection PubMed
description BACKGROUND: Malignant tumors of reproductive system seriously threaten women’s life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and control measures. METHODS: Annual death data for cervical cancer, uterine cancer and ovarian cancer were collected from the Chinese Cause of Death Surveillance. The crude mortality rate (CMR), age-standardized mortality rate (ASMR), annual percentage change (APC), and average APC (AAPC) were applied to analyze the trend of mortality. Loss of life expectancy (LLE) and years of life lost (YLL) were used to assess disease burden. RESULTS: From 2006 to 2020, there was no significant change in the total ASMR and standardized YLL rates of malignant tumors of the reproductive system, leading to an average LLE of 0.18 years. The YLL rate was the highest in the 55–59 age group. The mortality rate and disease burden of the three types of cancer have changed from uterine cancer higher than cervical cancer and ovarian cancer in 2006 to cervical cancer higher than ovarian cancer and uterine cancer in 2020. The ASMR and standardized YLL rate of uterine cancer showed a downward trend, and AAPC was − 5.21% (− 9.31% ~  − 0.91%) and − 6.07% (− 9.45% ~  − 2.58%), respectively. The mortality rates of cervical cancer and ovarian cancer remain high. CONCLUSION: The mortality and disease burden of malignant tumors of the female reproductive system in China are still at a high level. It is necessary to improve screening and prevention strategies as soon as possible, improve the techniques of diagnosis and treatment, and take adequate measures to protect women's life and health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02104-2.
format Online
Article
Text
id pubmed-9730658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97306582022-12-09 Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020 Han, Xiting Wang, Zhihong Huang, Dongmei Deng, Kehong Wang, Qian Li, Cancan Zhu, Jicun BMC Womens Health Research BACKGROUND: Malignant tumors of reproductive system seriously threaten women’s life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and control measures. METHODS: Annual death data for cervical cancer, uterine cancer and ovarian cancer were collected from the Chinese Cause of Death Surveillance. The crude mortality rate (CMR), age-standardized mortality rate (ASMR), annual percentage change (APC), and average APC (AAPC) were applied to analyze the trend of mortality. Loss of life expectancy (LLE) and years of life lost (YLL) were used to assess disease burden. RESULTS: From 2006 to 2020, there was no significant change in the total ASMR and standardized YLL rates of malignant tumors of the reproductive system, leading to an average LLE of 0.18 years. The YLL rate was the highest in the 55–59 age group. The mortality rate and disease burden of the three types of cancer have changed from uterine cancer higher than cervical cancer and ovarian cancer in 2006 to cervical cancer higher than ovarian cancer and uterine cancer in 2020. The ASMR and standardized YLL rate of uterine cancer showed a downward trend, and AAPC was − 5.21% (− 9.31% ~  − 0.91%) and − 6.07% (− 9.45% ~  − 2.58%), respectively. The mortality rates of cervical cancer and ovarian cancer remain high. CONCLUSION: The mortality and disease burden of malignant tumors of the female reproductive system in China are still at a high level. It is necessary to improve screening and prevention strategies as soon as possible, improve the techniques of diagnosis and treatment, and take adequate measures to protect women's life and health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-022-02104-2. BioMed Central 2022-12-07 /pmc/articles/PMC9730658/ /pubmed/36476597 http://dx.doi.org/10.1186/s12905-022-02104-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Han, Xiting
Wang, Zhihong
Huang, Dongmei
Deng, Kehong
Wang, Qian
Li, Cancan
Zhu, Jicun
Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
title Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
title_full Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
title_fullStr Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
title_full_unstemmed Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
title_short Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020
title_sort analysis of the disease burden trend of malignant tumors of the female reproductive system in china from 2006 to 2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730658/
https://www.ncbi.nlm.nih.gov/pubmed/36476597
http://dx.doi.org/10.1186/s12905-022-02104-2
work_keys_str_mv AT hanxiting analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020
AT wangzhihong analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020
AT huangdongmei analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020
AT dengkehong analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020
AT wangqian analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020
AT licancan analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020
AT zhujicun analysisofthediseaseburdentrendofmalignanttumorsofthefemalereproductivesysteminchinafrom2006to2020